BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Bao ZH, Hu C, Zhang YQ, Yu PC, Wang Y, Xu ZY, Fu HY, Cheng XD. Safety and efficacy of a programmed cell death 1 inhibitor combined with oxaliplatin plus S-1 in patients with Borrmann large type III and IV gastric cancers. World J Gastrointest Oncol 2024; 16(4): 1281-1295 [PMID: 38660643 DOI: 10.4251/wjgo.v16.i4.1281]
URL: https://www.wjgnet.com/1948-5204/full/v16/i4/1281.htm
Number Citing Articles
1
Junjie Xiong, Yu Zou, Yunlong Zhang, Fan He, Chenglin Tang, Kemei Zhong, Kun Qian. Safety and efficacy of laparoscopic radical gastrectomy after neoadjuvant chemotherapy plus immunotherapy: a retrospective cohort studyFrontiers in Immunology 2025; 16 doi: 10.3389/fimmu.2025.1672547
2
Zhiyuan Yu, Chen Liang, Qixuan Xu, Zhen Yuan, Miao Chen, Rui Li, Sixin Zhou, Peiyu Li, Bo Wei, Xudong Zhao. The safety and efficacy of neoadjuvant PD-1 inhibitor plus chemotherapy for patients with locally advanced gastric cancer: a systematic review and meta-analysisInternational Journal of Surgery 2025; 111(1): 1415 doi: 10.1097/JS9.0000000000002056
3
Chen Liang, Zhiyuan Yu, Siyu Hou, Chunzeng Jia, Yuxin Guan, Junfu Zheng, Yan Gao, Gailing Wu, Lei Niu, Pengji Gao, Lei Li. Therapeutic efficacy of multiple neoadjuvant regimens involving targeted therapy, immunotherapy and chemotherapy in gastric cancer: a systematic review and meta-analysisBMC Cancer 2025; 25(1) doi: 10.1186/s12885-025-15136-2
4
葱葱 杨. Clinical Applications and Resistance Challenges of PD-1/PD-L1 Inhibitors in Gastric CancerAdvances in Clinical Medicine 2025; 15(07): 641 doi: 10.12677/acm.2025.1572035